The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. Chief Executive Officer John Lechleiter plans to tell a technology conference today.
Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.
In trying to get sophisticated medicines to its neediest citizens, India is increasingly pitting its generic-pharmaceutical industry against international drugmakers, threatening their growth in emerging markets.
Eli Lilly & Co. Chief Executive Officer John Lechleiter said rising sales of the antidepressant Cymbalta and animal drugs stemmed losses from generic competition, helping the company’s earnings beat estimates.
China takes eight years longer on average to approve drugs than other major countries and U.S. drugmakers are looking at ways to help speed things up, Eli Lilly & Co. Chief Executive Officer John Lechleiter said.